• Most Popular
  • Most Shared

ViroPharma prices $225 mln in convertible notes

Tue Mar 20, 2007 11:37pm EDT

Stocks

   

NEW YORK, March 20 (Reuters) - Biotechnology company ViroPharma Inc. (VPHM.O) priced $225 million aggregate principal amount of convertible senior notes due in March 2017.

Bonds  |  IPOs

ViroPharma said that underwriters had been granted an option to purchase up to an additional $25 million aggregate principal amount of notes.

The company estimates that the net proceeds from this offering will be approximately $217.6 million after deducting estimated discounts, commissions and expenses.

The net proceeds of the offering will be used to fund general corporate purposes including strategic investments or acquisitions of products, technologies or complementary businesses.

Bonds
IPOs


More from Reuters

Photo

Democrats reach deal on health bill

WASHINGTON (Reuters) - Senate Democratic healthcare negotiators said they agreed on Tuesday to replace a government-run insurance option with a scaled-back non-profit plan and would seek cost estimates on the deal.

» More Top News
A pedestrian walks in lower Manhattan in New York, April 16, 2007. REUTERS/Eric Thayer
Analysis:

The boomer meltdown

The number of U.S. workers in their prime savings years peaks in 2010, affecting a key ratio that has impacted equities for 40 years. If history repeats itself, stocks are set for a funk.  Full Article 

Economy
Traders work on the main floor of the BM&F Bovespa stock exchange market in Sao Paulo October 10, 2008.REUTERS/Paulo Whitaker

Betting on emerging markets

There's still an upside in large-cap U.S. stocks, but BlackRock's Bob Doll says emerging markets have two things the developed world does not.  Full Article 

investment outlook summit